Brief: Abbisko Cayman Says PAN-FGFR Inhibitor ABSK091 Got Orphan Drug Designation In U.S.
07/03/2022 05:04
March 7 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* PAN-FGFR INHIBITOR ABSK091 OF UNIT GOT ORPHAN DRUG
DESIGNATION
IN U.S. FOR TREATMENT OF GASTRIC CANCER
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly